Gallardo-Aguilar J, Castillejos-Molina R, Feria-Bernal G

Language: Spanish
References: 19
Page: 394-398
PDF size: 1769.50 Kb.

ABSTRACT

Bladder adenocarcinoma is a rare tumor representing 0.5-3% of all bladder tumors. It has classically been considered to be a biologically more aggressive histological variant when compared with urothelial carcinoma. This is partly due to the fact that the majority of patients present with non-organ-confined disease at the time of diagnosis. Treatment options have been shown to be limited. Presently surgery is considered to be the only option with curative potential and satisfactory mid-term and long-term results. Among the surgical options, radical cystectomy has been proposed as standard treatment regardless of clinical stage. As alternatives, there have been series reporting satisfactory long-term results with partial cystectomy in selected patients with localized disease. This report presents a case of a primary bladder adenocarcinoma treated with partial cystectomy and patient’s oncological progression at five years.

REFERENCES

1. Dahm P, Gschwend J. Malignant Non-Urothelial Neoplasms of the Urinary Bladder: a review. Eur Urol 2003;44:672-81.

2. Hassan A, Kava B, Carmack A. Non-Urothelial Cancer of the Bladder. Urology. 2007;69(Suppl1):93-104.

3. Yakout H, Bissada N, Picklesimer F. Recurrent Superficial Papillary Adenocarcinoma of the Bladder. J Urol 2002;168:2538-9.

4. Messing E, Campbell-Walsh Urology. Chpt 75: Urothelial Tumors of the Bladder. Saunders Elsevier, 2007; pp.2407-2446.

5. Manunta A, Vincendeau S, Kiriakou G. Non-transitional cell bladder carcinomas. BJU Int 2005;95:497-502.

6. Ayala AG, Tamboli P, El-Bolkainy MN, Schoenberg M, et al. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs, capítulo II: Adenocarcinoma. IARC Press, 2002;pp.128-130.

7. El-Mekresh M, El-Baz M, Abol-Enein H. Primary adenocarcinoma of the urinary bladder: a report of 185 patients. Br J Urol 1998;82:206-12.

8. Grignon DJ, Ro JY, Ayala AG. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67:2165-72.

9. Fiter L, Gimeno F, Martin L. Signet-ring adenocarcinoma of the bladder. Urology 1993;41:30-3.

10. Corica FA, Husmann DA, Churchill BM. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term followup. Urology 1997;50:427-31.

11. Siefker-Radtke A, Gee J, Shen Y, et al. Multimodality Management of Urachal Carcinoma: the M.D. Anderson Cancer Center Experience. J Urol 2003;169:1295-8.

12. Ploeg M, Aben K, Hulsbergen-van de Kaa C, et al. Clinical Epidemiology of Nonurothelial Bladder Cancer: Analysis of The Netherlands Cancer Registry. J Urol 2010;183:915-20.

13. Lughezzani G, Sun M, Jeldres C, et al. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology 2010;75:376-81.

14. Gilligan T, Dreicer R. The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. Semin Oncol 2007;34:145-53.

15. Burrett AL, Epstein JI, Marshall FF. Adenocarcinoma of urinary bladder: classification and management. Urology 1991;37:315-21.

16. Cantellano M, Shuck C, Camarena H, et al. Cistectomía parcial como manejo de adenocarcinoma de vejiga. Rev Mex Urol 2009;69:181-4.

17. Messing E. Campbell-Walsh Urology. Chpt 75: Urothelial Tumors of the Bladder. Saunders, Elsevier, 2007;pp.2407-2446.

18. Holzbeierlein J, Lopez-Corona E, Bochner B, et al. Partial Cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004;172:878-81.

19. Kassouf W, Swanson D, Kamat A, et al. Partial cystectomy for muscle invasive Urothelial Carcinoma of the Bladder: A Contemporary Review of the M.D. Anderson Cancer Center Experience. J Urol 2006;175:2058-62.